Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

lts of operations could be adversely affected. These factors, and other factors, including, but not limited to those described in ViroPharma's annual report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission during 2008, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements.



                            VIROPHARMA INCORPORATED
                        Selected Financial Information


    Consolidated Statements of          Three months         Twelve months
     Operations:                           ended                ended
                                        December 31,          December 31,
    (in thousands, except per           -----------           -----------
     share data)                       2008      2007       2008       2007
                                       ----      ----       ----       ----

    Revenue:
    Net product sales                $50,020   $47,696   $232,307   $203,770
                                      ------    ------    -------    -------
    Revenue                           50,020    47,696    232,307    203,770
                                      ------    ------    -------    -------
    Costs and Expenses:
    Cost of sales (excluding
     amortization of product rights)   2,110     2,034      8,874      8,934
    Research and development          21,197    12,504     66,280     35,869
    Selling, general and
     administrative                   22,357    12,710     65,424     37,051
    Intangible amortization            5,505     1,401     10,809      6,120
    Impairment of fixed assets
     held for sale                     2,265         -      2,265          -
              
'/>"/>
SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)...   Meditope Biosciences, Inc ., a biotechnology company ... announced presentation of data demonstrating the use of its ... (ADCs). The data were presented in an abstract at the ... Philadelphia . "We ... the many commercial applications that may be possible for ...
(Date:4/20/2015)... Whitehouse Laboratories is pleased and overly excited ... Food and Drug Administration (FDA) inspection and received no ... GMP compliance inspection, as based upon 21CFR Parts 210 ... 6th and was granted NAI (no action indicated) status. ... Good Manufacturing Practice (GMP) quality system required by the ...
(Date:4/17/2015)... Calif. , April 17, 2015 /PRNewswire/ ... received a SBIR grant from the National ... National Institutes of Health (NIH). The grant ... efforts in the development of breakthrough genomic ... using specially fabricated substrates. Centrillion has been ...
(Date:4/17/2015)... April 17, 2015 CIO Review ( ... its 20 Most Promising Pharma and Life Science Technology ... MediSpend global compliance software platform for life sciences companies. ... by a panel of experts and members of CIO ... “MMIS’s MediSpend Platform has been on our radar for ...
Breaking Biology Technology:Meditope Biosciences Presents Data At The American Association Of Cancer Research (AACR) Annual Meeting Validating Its SnAP Technology Platform 2Whitehouse Laboratories Completes FDA Inspection with No Form 483 – No Observations 2Whitehouse Laboratories Completes FDA Inspection with No Form 483 – No Observations 3MMIS Chosen by CIO Review as Top 20 Most Promising Pharma and Life Science Technology Solution Providers 2015 2
... Nikon-Exclusive Perfect Focus System and High-Speed Motorization Meets ... and Pharmaceutical Science Research Needs, MELVILLE, N.Y., ... has combined streamlined component automation,with speeds more than ... launch of the Eclipse Ti-E inverted research microscope. ...
... ... - Third Quarter EPS of $0.70 per Basic Share, or $0.66 per Diluted Share, - ... ... United,Therapeutics Corporation (Nasdaq: UTHR ) today announced its results of,operations for the quarter ended September ...
... Biosciences,Inc. (Nasdaq: NBIX ) today announced that it ... and commercialization of indiplon,in Japan with Dainippon Sumitomo Pharma ... (NDA) for indiplon in the US for the,treatment of ... FDA with a,PUDFA action date of December 12, 2007. ...
Cached Biology Technology:Nikon Instruments Launches New Eclipse Ti-E Fully-Integrated, Motorized Inverted Microscope 2Nikon Instruments Launches New Eclipse Ti-E Fully-Integrated, Motorized Inverted Microscope 3United Therapeutics Reports Third Quarter 2007 Financial Results 2United Therapeutics Reports Third Quarter 2007 Financial Results 3United Therapeutics Reports Third Quarter 2007 Financial Results 4United Therapeutics Reports Third Quarter 2007 Financial Results 5United Therapeutics Reports Third Quarter 2007 Financial Results 6United Therapeutics Reports Third Quarter 2007 Financial Results 7United Therapeutics Reports Third Quarter 2007 Financial Results 8United Therapeutics Reports Third Quarter 2007 Financial Results 9Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan 2Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan 3
(Date:3/30/2015)... Mar. 26, 2015 Research and Markets ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... forecast the Global Gesture Recognition market in Automotive Sector ... period 2013-2018. Gesture recognition is the ability ... gestures of an individual. Gesture recognition technology can be ...
(Date:3/24/2015)... PALM BEACH GARDENS, Fla. , March 24, ... of biometric identity management solutions, today announced that ... enabling premium clothing accessory retailer Goorin Bros ... login. The Crossmatch biometrics-based solution secures access to ... customers from the increased risk of data breaches. ...
(Date:3/20/2015)... Mar. 20, 2015 Research and Markets ... of the "India Sensors Market Forecast and ... The sensor market is projected to grow ... Consumer electronics, automotive, industrial and healthcare sectors ... the country. In addition, adoption of MEMS technology ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... from Holzmaden (Germany) that perished 182 million years ago ... the extinct marine reptile is almost immaculately preserved and ... in their anatomical position. The bones of the ichthyosaur ... part, they lie scattered outside the body of the ...
... proceeds very slowly. But the slow-growing bacteria living many ... global storage of organic carbon and have a long-term effect ... the University of Rhode Island have developed a new method ... Their findings were published last week in the ...
... the Woods Hole Oceanographic Institution (WHOI), University of Hawaii, ... systematic study of life in the deepest marine habitat ... floor ranging from 19,685 to 36,089 feet (6,000 to ... the technical challenges involved in reaching this depth, known ...
Cached Biology News:Exploding dinosaur hypothesis implodes 2Oceanographers develop method for measuring the pace of life in deep sediments 2WHOI researchers, collaborators receive $1.4 million grant to study life in ocean's greatest depths 2WHOI researchers, collaborators receive $1.4 million grant to study life in ocean's greatest depths 3WHOI researchers, collaborators receive $1.4 million grant to study life in ocean's greatest depths 4
... a full length insert sequencing service for ... and fosmids. Agencourt utilizes unique library ... There are several features that allow ... with rapid turnaround including our patented magnetic ...
High-throughput DNA sequencing of any library. Just give us your transformation mixture, and we'll do the rest. ABI 3730xl's yield the longest read lengths available. LIMS tracking utilizing Geospiza...
... Fully automated, GLP-compliant Facility , Galaxy LIMS, ... , Highly experienced scientists ,We offer individual ... or full plasmids for single or double ... used when the DNA of interest is ...
Great for biotinylating DNA/RNA probes...
Biology Products: